Drug application
SOLIQUA 100/33 (INSULIN GLARGINE, LIXISENATIDE)
Drugs@FDA BLA 208673 · SANOFI-AVENTIS US
Key facts
| Drug name | SOLIQUA 100/33 |
|---|---|
| Active ingredients | INSULIN GLARGINE, LIXISENATIDE |
| Application type | BLA |
| Application number | 208673 |
| Company | SANOFI-AVENTIS US |
| Dosage forms | SOLUTION, SUBCUTANEOUS |
| Strength | 300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML) |
| Marketing status | Prescription |
| Reference listed drug | No |
| Latest submission class | Type 4 - New Combination |
| Latest submission status date | Nov 21, 2016 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 10–99 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: